DHR Stock Analysis — Danaher Corporation
Sector: Healthcare
AI Verdict
Danaher is cheap for the growth on offer at 20.2x forward earnings, but you’re betting that its M&A-driven recurring revenue model delivers the 59.4% EPS jump analysts expect.
Competitive Moat
Danaher builds a defensible position through its portfolio of specialized life sciences, diagnostics, and environmental technologies, with recurring revenue from consumables and a proven M&A playbook. Its scale and integration of proprietary lab automation tools create switching costs for research and clinical customers.
Summary
Danaher is flashing an RSI of 27.0, signaling the stock is deeply oversold after a -15.54% one-year return.
Where It Stands
Danaher trades at 20.2x next year's earnings, a discount to the healthcare sector median of 22x, with analysts projecting a 59.4% EPS jump and the stock showing an oversold RSI of 27.0.
Key Metrics
- RSI: 27 — Oversold
- Trailing P/E: 32.3x
- Forward P/E: 20.2x
- PEG Ratio: 0.57
- Earnings Growth: +0.6%
- Revenue Growth: +0.0%
- Market Cap: $118.2B
- Dividend Yield: 0.01%
- 1-Year Return: -15.54%
- 52-Week High: $242.80
- 52-Week Low: $160.93
Analyst Consensus
26 Buy · 4 Hold · 0 Sell (30 analysts)
Bull Case
You’re paying 20.2x forward earnings for a forecasted 59.4% EPS surge, which is cheap for this level of growth if Danaher’s recurring revenue moat holds up.
Bear Case
If the P/E multiple reverts to the sector median of 22x but earnings growth disappoints, the stock could see further downside after its -15.54% one-year return and current oversold RSI.
Catalyst to Watch
Watch for upcoming earnings and guidance updates — if forward EPS growth near 59.4% is confirmed, the current valuation could quickly look too low.